Literature DB >> 20080755

Immune effectors required for hepatitis B virus clearance.

Priscilla L Yang1, Alana Althage, Josan Chung, Holly Maier, Stefan Wieland, Masanori Isogawa, Francis V Chisari.   

Abstract

To better define the mechanism(s) likely responsible for viral clearance during hepatitis B virus (HBV) infection, viral clearance was studied in a panel of immunodeficient mouse strains that were hydrodynamically transfected with a plasmid containing a replication-competent copy of the HBV genome. Neither B cells nor perforin were required to clear the viral DNA transcriptional template from the liver. In contrast, the template persisted for at least 60 days at high levels in NOD/Scid mice and at lower levels in the absence of CD4(+) and CD8(+) T cells, NK cells, Fas, IFN-gamma (IFN-gamma), IFN-alpha/beta receptor (IFN-alpha/betaR1), and TNF receptor 1 (TNFR1), indicating that each of these effectors was required to eliminate the transcriptional template from the liver. Interestingly, viral replication was ultimately terminated in all lineages except the NOD/Scid mice, suggesting the existence of redundant pathways that inhibit HBV replication. Finally, induction of a CD8(+) T cell response in these animals depended on the presence of CD4(+) T cells. These results are consistent with a model in which CD4(+) T cells serve as master regulators of the adaptive immune response to HBV; CD8(+) T cells are the key cellular effectors mediating HBV clearance from the liver, apparently by a Fas-dependent, perforin-independent process in which NK cells, IFN-gamma, TNFR1, and IFN-alpha/betaR play supporting roles. These results provide insight into the complexity of the systems involved in HBV clearance, and they suggest unique directions for analysis of the mechanism(s) responsible for HBV persistence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20080755      PMCID: PMC2818933          DOI: 10.1073/pnas.0913498107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  Viral clearance without destruction of infected cells during acute HBV infection.

Authors:  L G Guidotti; R Rochford; J Chung; M Shapiro; R Purcell; F V Chisari
Journal:  Science       Date:  1999-04-30       Impact factor: 47.728

2.  Pathogenetic effector function of CD4-positive T helper 1 cells in hepatitis B virus transgenic mice.

Authors:  A Franco; L G Guidotti; M V Hobbs; V Pasquetto; F V Chisari
Journal:  J Immunol       Date:  1997-08-15       Impact factor: 5.422

3.  Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system.

Authors:  S R Yant; L Meuse; W Chiu; Z Ivics; Z Izsvak; M A Kay
Journal:  Nat Genet       Date:  2000-05       Impact factor: 38.330

4.  Differential target cell sensitivity to CTL-activated death pathways in hepatitis B virus transgenic mice.

Authors:  Y Nakamoto; L G Guidotti; V Pasquetto; R D Schreiber; F V Chisari
Journal:  J Immunol       Date:  1997-06-15       Impact factor: 5.422

5.  DNA immunization induces antibody and cytotoxic T cell responses to hepatitis B core antigen in H-2b mice.

Authors:  A Kuhöber; H P Pudollek; K Reifenberg; F V Chisari; H J Schlicht; J Reimann; R Schirmbeck
Journal:  J Immunol       Date:  1996-05-15       Impact factor: 5.422

6.  Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes.

Authors:  L G Guidotti; T Ishikawa; M V Hobbs; B Matzke; R Schreiber; F V Chisari
Journal:  Immunity       Date:  1996-01       Impact factor: 31.745

7.  Hepatitis B virus replication is cell cycle independent during liver regeneration in transgenic mice.

Authors:  L G Guidotti; B Matzke; F V Chisari
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

8.  Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver.

Authors:  M Adachi; S Suematsu; T Kondo; J Ogasawara; T Tanaka; N Yoshida; S Nagata
Journal:  Nat Genet       Date:  1995-11       Impact factor: 38.330

9.  High-level hepatitis B virus replication in transgenic mice.

Authors:  L G Guidotti; B Matzke; H Schaller; F V Chisari
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

10.  Natural killer T cell activation inhibits hepatitis B virus replication in vivo.

Authors:  K Kakimi; L G Guidotti; Y Koezuka; F V Chisari
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307

View more
  100 in total

1.  High persistence rate of hepatitis B virus in a hydrodynamic injection-based transfection model in C3H/HeN mice.

Authors:  Xiu-Hua Peng; Xiao-Nan Ren; Li-Xiang Chen; Bi-Sheng Shi; Chun-Hua Xu; Zhong Fang; Xue Liu; Jie-Liang Chen; Xiao-Nan Zhang; Yun-Wen Hu; Xiao-Hui Zhou
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

2.  Tumor necrosis factor-alpha blockage therapy impairs hepatitis B viral clearance and enhances T-cell exhaustion in a mouse model.

Authors:  I-Tsu Chyuan; Hwei-Fang Tsai; Horng-Tay Tzeng; Chi-Chang Sung; Chien-Sheng Wu; Pei-Jer Chen; Ping-Ning Hsu
Journal:  Cell Mol Immunol       Date:  2015-02-09       Impact factor: 11.530

3.  Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus.

Authors:  Gregor Ebert; Simon Preston; Cody Allison; James Cooney; Jesse G Toe; Michael D Stutz; Samar Ojaimi; Hamish W Scott; Nikola Baschuk; Ueli Nachbur; Joseph Torresi; Ruth Chin; Danielle Colledge; Xin Li; Nadia Warner; Peter Revill; Scott Bowden; John Silke; C Glenn Begley; Marc Pellegrini
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-20       Impact factor: 11.205

4.  Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis.

Authors:  Gregor Ebert; Cody Allison; Simon Preston; James Cooney; Jesse G Toe; Michael D Stutz; Samar Ojaimi; Nikola Baschuk; Ueli Nachbur; Joseph Torresi; John Silke; C Glenn Begley; Marc Pellegrini
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-20       Impact factor: 11.205

Review 5.  New therapeutic vaccination strategies for the treatment of chronic hepatitis B.

Authors:  Jia Liu; Anna Kosinska; Mengji Lu; Michael Roggendorf
Journal:  Virol Sin       Date:  2014-01-17       Impact factor: 4.327

6.  Viral hepatitis: The bumpy road to animal models for HBV infection.

Authors:  Ulrike Protzer
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-04-12       Impact factor: 46.802

Review 7.  The role of innate immunity in HBV infection.

Authors:  Qiuju Han; Cai Zhang; Jian Zhang; Zhigang Tian
Journal:  Semin Immunopathol       Date:  2012-07-20       Impact factor: 9.623

8.  Identification of an intrahepatic transcriptional signature associated with self-limiting infection in the woodchuck model of hepatitis B.

Authors:  Simon P Fletcher; Daniel J Chin; Donavan T Cheng; Palanikumar Ravindran; Hans Bitter; Lore Gruenbaum; Paul J Cote; Han Ma; Klaus Klumpp; Stephan Menne
Journal:  Hepatology       Date:  2013-01       Impact factor: 17.425

9.  Recombinant covalently closed circular hepatitis B virus DNA induces prolonged viral persistence in immunocompetent mice.

Authors:  Zhihua Qi; Gaiyun Li; Hao Hu; Chunhui Yang; Xiaoming Zhang; Qibin Leng; Youhua Xie; Demin Yu; Xinxin Zhang; Yueqiu Gao; Ke Lan; Qiang Deng
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

10.  Molecular mechanisms of HBeAg in persistent HBV infection.

Authors:  Li-Min Chen; Xue-Gong Fan; Jing Ma; Bo He; Yong-Fang Jiang
Journal:  Hepatol Int       Date:  2016-05-18       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.